EOElizabeth Michel Ortega-Rocha

Elizabeth Michel Ortega-Rocha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elizabeth Michel Ortega-Rocha has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The interplay between epidermal barrier distribution, microbiota composition, and immune infiltrate defines and stratifies psoriasis patients and is associated with disease severity

    by Elizabeth M. Ortega Rocha, Paul Hernández-Herrera, Sofia V. de Los Santos- Carmona, Saraí G De León-Rodríguez, Ángel Juárez-Flores, Vadim Pérez-Koldenkova, Octavio Castro-Escamilla, Samira Muñoz-Cruz, Alicia Lemini-López, Laura C. Bonifaz


  • Open Access

    [Translational medicine in dermatology: experience in the Specialties Hospital of the 21st Century National Medical Center].

    by Elizabeth Michel Ortega-Rocha, Brenda Hernández-Rico, Laura Cecilia Bonifaz-Alfonzo, Alicia Lemini-López

    Through multidisciplinary research, translational medicine allows a comprehensive approach to diseases in order to provide patients with adequate treatment, whose aim is personalized and precision medicine. In this context, the Cellular Immunology Laboratory of the Immunochemistry Research Unit, and the Dermatology Service of the 21st Century National Medical Center's Specialties Hospital (Hospital de Especialidades del Centro Médico Nacional Siglo XXI) have achieved a partnership that aspires to provide better quality patient care. This objective is achieved by evaluating the inflammatory skin infiltrates in different pathologies to observe changes in local immunity related to the response to treatment, and with the disease progression distinguish between dermatological diseases, highlight the importance of comprehensive skin care, and make decisions about treatment choice. This article will describe the results obtained from different research protocols (derived from this collaboration) in patients with different dermatoses such as warts, squamous cell carcinoma, mycosis fungoides and psoriasis. The evidence presented highlights the importance of collaborative work between clinical services and research laboratories so that scientific knowledge can be translated towards the comprehensive management of patients and towards personalized and precision medicine.

  • Open Access

    Association of Pathogenic Th17 Cells with the Disease Severity and Its Potential Implication for Biological Treatment Selection in Psoriasis Patients

    by Cristina Aguilar-Flores, Octavio Castro-Escamilla, Elizabeth M. Ortega-Rocha, César Maldonado-García, Fermín Jurado-Santa Cruz, Gibrán Pérez-Montesinos, Alicia Lemini-López, Laura C. Bonifaz

    Psoriasis is an inflammatory autoimmune disease characterized by cutaneous lesions in plaques. It has been proposed that the immune response has a key role in the disease progression. Particularly, the Th17 cells through IL-17 can contribute to maintain the inflammatory process. The pathogenic Th17 phenotype has been described in human diseases and associated with high severity in inflammatory experimental models. However, it is not clear if the pathogenic phenotype could be present in the skin and peripheral blood as well as its possible association to severity in psoriasis. In the lesional skin, we found high infiltration of Th17 cells and the pathogenic phenotype, finding a correlation between the frequency of Th17 cells and the Psoriasis Area and Severity Index (PASI) score. In peripheral blood, we observed a pool of Th17 lymphocytes with potential to acquire pathogenic features. Interestingly, the percentage of pathogenic Th17 cells (CD4+ RORγt+ IFN-γ+) correlates with disease severity. Moreover, we distinguished three groups of patients based on their IL-17/IFN-γ production by Th17 lymphocytes, which seems to be related with a dynamic or stable potential to express these cytokines. Remarkably, we evaluated the cytokine production by Th17 cells as an immunological marker for the adequate selection of biologic therapy. We found that patients analyzed by this immunological approach and treated with antibodies against IL-17 and TNFα showed great improvement depicted by reduction in PASI and Dermatology Life Quality Index (DLQI) score as well as the percentage of Body Surface Area (BSA). Altogether, our results highlight the importance of the assessment of the pathogenic phenotype in Th17 cells as an immune personalized analysis with the potential to support the therapy choice in the clinical practice.